Effect of Remifentanil Boluses on Hemodynamics in Skull Pin Insertion

NCT ID: NCT01056224

Last Updated: 2010-01-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-05-31
• Study Completion Date: 2010-01-31

Brief Summary

Skull pin insertion during craniotomies is a brief, intensely stimulating, painful stimuli occurring during the conduct of a neurosurgical or spine anesthetic. Remifentanil is an ultra short acting opioid that has been successfully used to blunt hemodynamic responses in a wide variety of clinical scenarios. It is our intention to ascertain the optimal dose for blunting the hemodynamic response to skull pin insertion using remifentanil.

Detailed Description

Skull pin insertion is commonly required for craniotomies and cervical spine surgery. It is a brief but highly stimulating maneuver performed following induction, during a period of light anesthesia, and may cause significant rise in blood pressure, heart rate and intracranial pressure if not anticipated and treated.

A wide variety of methods have been shown to be effective at blunting this hypertensive response. These include intravenous agents such as fentanyl, sufentanil, clonidine, ketamine and magnesium sulphate, local anesthetic methods such as injection at pin sites or full scalp blocks, deepening the volatile agent, oral premedication or a combination of these methods. There is no consensus on which of these methods is the best. Many anesthesiologists simply use boluses of propofol - a reliable way of accomplishing this effect with a familiar drug. It is also very common for anesthesiologists to use remifentanil, by increasing the infusion rate and or bolusing.

Remifentanil is an ultra-short acting opiate with such rapid onset and offset, that it is most easily and safely delivered by infusion. Increasingly in the literature, however, are reports of remifentanil administered as boluses rather than infusions. Boluses may be ideal for very short stimulating procedures such as intubation and skull pin fixation where a quick onset and offset are desired. Although the safety of bolusing remifentanil has been established in many studies , some authors are still apprehensive . Care must be taken to avoid bolusing with greater doses than required since this may lead to bradycardia and hypotension. In non-ventilated patients, respiratory depression is common and chest wall rigidity may occur at doses larger than 4ug/kg9.

Different bolus dose-effect studies have recommended the following for remifentanil in a variety of clinical settings:

• 3-5ug/kg with propofol 2mg/kg for intubation without muscle relaxants ,
• 2ug/kg with propofol TCI (>4ug/ml) and cisatracurium for intubation (no additional hemodynamic benefit using 4ug/kg)
• 1-1.25ug/kg for rapid sequence intubation with thiopentone 5-7mg/kg and succinylcholine 1mg/kg
• ED50 of 1.7ug/kg and ED95 of 2.88ug/kg for good to excellent intubating conditions in both infants and children (when used with 10ug/kg glycopyrrolate and 4mg/kg propofol)
• 3ug/kg (plus 4mg/kg propofol) provides similar intubating conditions when used in place of succinylcholine 2mg/kg for intubation in infants8

Remifentanil is not currently recommended for the following settings:

• As a sole agent for loss of consciousness with a high ED50 of 12ug/kg, lack of reliability and muscle rigidity common at such high doses
• Wide interindividual variability limit its use for labor analgesia (0.2-0.8ug/kg, median dose of 0.4ug/kg)

In neurosurgery, it is common to administer remifentanil as an infusion. Optimal infusion rates have already been investigated for intracranial surgery . However it is increasingly common to administer remifentanil as a bolus particularly during skull pin fixation, due to the desirable quick onset and offset, and there are no studies at present that have investigated optimal dose requirements for boluses in this setting.

At our institution we commonly administer remifentanil as a bolus during skull pin fixation and are interested in determining which bolus doses are safe and effective

Conditions

Skull Pin Insertion; Short Duration Analgesia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

1.25 ug/kg normo-tensive 20-40 year olds

A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.

Group Type: EXPERIMENTAL

Remifentanil

Intervention Type: DRUG

A single bolus dose of Remifentanil will be administered at the time of skull pin insertion

1.5 ug/kg normo-tensive 20-40 year olds

A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.

Group Type: EXPERIMENTAL

Remifentanil

Intervention Type: DRUG

A single bolus dose of Remifentanil will be administered at the time of skull pin insertion

1.75 ug/kg normo-tensive 20-40 year olds

A single bolus dose of 1.75 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 20 to 40 years old.

Group Type: EXPERIMENTAL

Remifentanil

Intervention Type: DRUG

A single bolus dose of Remifentanil will be administered at the time of skull pin insertion

1 ug/kg normo-tensive 65-75 year olds

A single bolus dose of 1 microgram per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old.

Group Type: EXPERIMENTAL

Remifentanil

Intervention Type: DRUG

A single bolus dose of Remifentanil will be administered at the time of skull pin insertion

1.25 ug/kg normo-tensive 65-75 year olds

A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old.

Group Type: EXPERIMENTAL

Remifentanil

Intervention Type: DRUG

A single bolus dose of Remifentanil will be administered at the time of skull pin insertion

1.5 ug/kg normo-tensive 65-75 year olds

1.5 ug/kg normo-tensive 65-75 year olds

A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in normo-tensive patients aged 65 to 75 years old.

Group Type: EXPERIMENTAL

Remifentanil

Intervention Type: DRUG

A single bolus dose of Remifentanil will be administered at the time of skull pin insertion

1 ug/kg hyper-tensive 65-75 year olds

A single bolus dose of 1 microgram per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.

Group Type: EXPERIMENTAL

Remifentanil

Intervention Type: DRUG

A single bolus dose of Remifentanil will be administered at the time of skull pin insertion

1.25 ug/kg hyper-tensive 65-75 year olds

A single bolus dose of 1.25 micrograms per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.

Group Type: EXPERIMENTAL

Remifentanil

Intervention Type: DRUG

A single bolus dose of Remifentanil will be administered at the time of skull pin insertion

1.5 ug/kg hyper-tensive 65-75 year olds

A single bolus dose of 1.5 micrograms per kilogram body weight will be administered at the time of skull pin insertion in hyper-tensive patients aged 65 to 75 years old.

Group Type: EXPERIMENTAL

Remifentanil

Intervention Type: DRUG

A single bolus dose of Remifentanil will be administered at the time of skull pin insertion

Interventions

Remifentanil

A single bolus dose of Remifentanil will be administered at the time of skull pin insertion

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Patients requiring skull pin fixation and general anesthesia for:

• Elective cervical spine surgery
• Elective craniotomies/brain tumor resection
• Elective transsphenoidal pituitary hypophysectomies

Exclusion Criteria

Patients with evidence of raised intracranial pressure:

• GSC < 15
• Radiological evidence of significant rise in ICP (e.g. midline shift)
• Vascular anomalies in the brain

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Health Network, Toronto

OTHER

Sponsor Role: lead

Responsible Party

University Health Network

Principal Investigators

Atul Prabhu, MD

Role: PRINCIPAL_INVESTIGATOR

University Health Network, Toronto

Locations

Toronto Western Hospital

Toronto, Ontario, Canada

Countries

Canada

Other Identifiers

05-0684-B

Identifier Type: -

Identifier Source: org_study_id